Which manufacturer is Inalise (Ihelai) produced by and its corporate background introduction?

Inavolisib is an oral small molecule selective PI3Kα inhibitor, mainly used to treat patients with breast cancer and other solid tumors related to PIK3CA gene mutations. The drug specifically inhibits the PI3Kα signaling pathway and blocks downstream AKT/mTOR signaling, thereby inhibiting tumor cell proliferation and promoting apoptosis. Since PIK3CA mutations occur more frequently in breast cancer and some solid tumors, inalise provides a new option for targeted therapy for this type of patients.

Inariset is developed and produced by the Swiss pharmaceutical companyNovartis (Novartis Pharmaceuticals). Founded in 1996 and headquartered in Basel, Switzerland, Novartis is one of the world's leading multinational pharmaceutical companies. Its business covers innovative drug research and development, generic drugs, ophthalmic drugs and vaccines. Novartis has rich R&D experience in the field of oncology and has a number of innovative targeted drugs and immunotherapy products. Inaliside is one of its important achievements in the layout of precision tumor treatment.

During the research and development process of inariside, the company focuses on the combination of preclinical research and precise patient screening. Through a large number of molecular biology experiments and animal model verification, the specificity and efficacy of the drug in PIK3CA mutated tumors were determined, and the tolerability and safety were systematically evaluated in early clinical trials. This research and development model reflects Novartis’ scientific research strength in the field of targeted tumor drugs and its practice of the concept of precision treatment for patients.

In addition, Novartis Pharmaceuticals has a complete pharmaceutical production and supply chain system worldwide to ensure high-standard quality control of inariside from research and development to marketing. The company actively cooperates with regulatory agencies in various countries to accelerate the drug approval and marketing process, while providing clinical support and patient assistance programs to improve drug accessibility. With its strong R&D background and international operation capabilities, Inalise is expected to play an important role in the field of precision tumor treatment and provide new treatment options for patients related to PIK3CA mutations.

Reference link:https://www.drugs.com